ProQR Therapeutics - PRQR Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRQR shares.
View PRQR analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1 year target prices for ProQR Therapeutics' stock. Their PRQR share price forecasts range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.90 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for PRQR or view top-rated stocks among Wall Street analysts.

ProQR Therapeutics' stock was trading at $3.70 on January 1st, 2023. Since then, PRQR stock has decreased by 3.0% and is now trading at $3.59.
View the best growth stocks for 2023 here.

ProQR Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,620,000 shares, an increase of 21.8% from the February 28th total of 1,330,000 shares. Based on an average daily trading volume, of 2,750,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.5% of the shares of the company are short sold.
View ProQR Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our PRQR earnings forecast.

ProQR Therapeutics (NASDAQ:PRQR) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.01. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 76.32% and a negative net margin of 2,075.42%.

Direxion mRNA ETF holds 19,698 shares of PRQR stock, representing 2.13% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

ProQR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include M28 Capital Management LP (2.68%), Opaleye Management Inc. (2.05%), Marshall Wace LLP (0.59%), Morgan Stanley (0.53%), Two Sigma Investments LP (0.43%) and Millennium Management LLC (0.26%).

Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRQR stock can currently be purchased for approximately $3.59.

ProQR Therapeutics (NASDAQ:PRQR) has a market capitalization of $255.93 million and generates $1.60 million in revenue each year. The biopharmaceutical company earns $-72,900,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

The company employs 1,504 workers across the globe.

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The official website for the company is www.proqr.com. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at ir@proqr.com.